Trial · NCT01231750
Efficacy of Topical Capsaicin Cream for Stable Angina
NCT01231750, Phase 3, Terminated, Neal Weintraub; results first posted 2015-06-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Topical Capsaicin Cream for Stable Angina. Trials, record NCT01231750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01231750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Topical Capsaicin Cream for Stable Angina
- NCT number
- NCT01231750
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 7 participants, actual
- Lead sponsor
- Neal Weintraub
- Conditions
- Stable Angina
- Interventions
- Capsaicin, Placebo cream
- First posted
- 2010-11-01
- Last updated
- 2015-06-25
- Results first posted
- 2015-06-25
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Symptom-limited Exercise Duration as an Indicator of Exercise Capacity | Application was 45 minutes prior to exercise | Subjects walked on the treadmill as long as they could tolerate, symptom-limited. |
| Primary | Time-to-onset of 1mm ST Segment Depression | Application was 45 minutes prior to exercise | Continuous ECG was recorded during exercise. ECG was reviewed by a board-certified cardiologist. |
| Primary | Time-to-onset of Angina or Angina Equivalent Symptoms | Application was 45 minutes prior to exercise | Onset of angina or angina-equivalent symptoms was assessed from beginning of exercise. |
| Primary | Maximal ST Depression | Application was 45 minutes prior to exercise | Exercise ECG data was reviewed by a board certified cardiologist to assess maximal ST depression. |
| Primary | Maximal Estimated Workload (in METS) | Application was 45 minutes prior to exercise | Maximal estimated workload (in METS) was measured during exercise tolerance test (ETT). |
| Primary | Magnitude of Reversible Perfusion Defect in SPECT With Wall Motion Assessment (Phase 2) | Phase 2 was not done. | Phase 2 of the study involving nuclear imaging was not done because the study was stopped early for lack of enrollment. |
| Primary | Severity of Angina Was Measured. | Application was 45 minutes prior to exercise | Severity of angina was measured using numerical score 1 to 10, where 10 is the worst intensity and 1 is the least. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Symptom-limited Exercise Duration as an Indicator of Exercise Capacity | Application was 45 minutes prior to exercise | Data collected are no longer accessible. | ||
| PRIMARY | Time-to-onset of 1mm ST Segment Depression | Application was 45 minutes prior to exercise | Data collected are no longer accessible. | ||
| PRIMARY | Time-to-onset of Angina or Angina Equivalent Symptoms | Application was 45 minutes prior to exercise | Data collected are no longer accessible. | ||
| PRIMARY | Maximal ST Depression | Application was 45 minutes prior to exercise | Data collected are no longer accessible. | ||
| PRIMARY | Maximal Estimated Workload (in METS) | Application was 45 minutes prior to exercise | Data collected are no longer accessible. | ||
| PRIMARY | Magnitude of Reversible Perfusion Defect in SPECT With Wall Motion Assessment (Phase 2) | Phase 2 was not done. | |||
| PRIMARY | Severity of Angina Was Measured. | Application was 45 minutes prior to exercise |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 0.1% Capsaicin Cream First, Then Placebo | 3 | |
| Overall Study | STARTED | Placebo First, Then 0.1% Capsaicin | 4 | |
| Overall Study | COMPLETED | 0.1% Capsaicin Cream First, Then Placebo | 3 | |
| Overall Study | COMPLETED | Placebo First, Then 0.1% Capsaicin | 4 | |
| Overall Study | NOT COMPLETED | 0.1% Capsaicin Cream First, Then Placebo | 0 | |
| Overall Study | NOT COMPLETED | Placebo First, Then 0.1% Capsaicin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 0.1% Capsaicin Cream First, Then Placebo | ||
| Total, all-cause mortality | Placebo First, Then 0.1% Capsaicin | ||
| Total, other adverse events | 0.1% Capsaicin Cream First, Then Placebo | 0 | 3 |
| Total, other adverse events | Placebo First, Then 0.1% Capsaicin | 0 | 4 |
| Total, serious adverse events | 0.1% Capsaicin Cream First, Then Placebo | 0 | 3 |
| Total, serious adverse events | Placebo First, Then 0.1% Capsaicin | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| 0.1% Capsaicin Cream First, Then Placebo vs Placebo First, Then 0.1% Capsaicin: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01231750
GET https://conductscience.org/api/trials/v1/NCT01231750/registered